Amgen (AMGN), AstraZeneca (AZN) Say Tezepelumab Is First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
Go back to Amgen (AMGN), AstraZeneca (AZN) Say Tezepelumab Is First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma
February 26, 2021 9:00 AM EST
THOUSAND OAKS, Calif., Feb. 26, 2021 /PRNewswire/ --Â Amgen (NASDAQ: AMGN) and AstraZeneca today announced positive full results from the pivotal NAVIGATOR Phase 3 trial, which showed the potential of tezepelumab to be a first-in-class medicine in severe asthma. When added to standard of care (SoC),... More